Phase 1Recruiting
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed/Refractory (R/R) CD19+ B-cell Malignancies
- Sponsor
- Umoja Biopharma (Industry)
- Enrolment
- 106 planned
- Conditions
- Lymphoma, B-Cell; Lymphoma, Non-Hodgkin (NHL); Lymphoma, Large B-Cell, Diffuse (DLBCL); Chronic Lymphocytic Leukemia (CLL)
- Interventions
- UB-VV111; rapamycin
- Ages
- adults, older adults
- Registry
- NCT06528301
From the registry
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
Primary outcomes
- Percentage of participants with common adverse events (AEs)